S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
NASDAQ:FOLD

Amicus Therapeutics Stock Forecast, Price & News

$10.45
-0.68 (-6.11%)
(As of 12/3/2021 12:00 AM ET)
Add
Compare
Today's Range
$10.32
$11.21
50-Day Range
$9.55
$12.44
52-Week Range
$8.60
$25.39
Volume
1.75 million shs
Average Volume
2.87 million shs
Market Capitalization
$2.91 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.17
30 days | 90 days | 365 days | Advanced Chart
Receive FOLD News and Ratings via Email

Sign-up to receive the latest news and ratings for Amicus Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


Amicus Therapeutics logo

About Amicus Therapeutics

Amicus Therapeutics, Inc. operates as a biotechnology company. The firm focuses on discovering, developing and delivering medicines for people living with metabolic diseases. Its product portfolio includes first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants, a novel, clinical-stage, treatment paradigm for Pompe disease and a rare disease gene therapy portfolio. The company was founded by John Francis Crowley on February 4, 2002 and is headquartered in Philadelphia, PA.

Headlines

Amicus Therapeutics (NASDAQ:FOLD) Shares Gap Up to $11.34
November 15, 2021 |  americanbankingnews.com
Stifel Nicolaus Upgrades Amicus Therapeutics (NASDAQ:FOLD) to Buy
November 15, 2021 |  americanbankingnews.com
Amicus (FOLD) Stock Down on Q3 Earnings and Revenue Miss
November 10, 2021 |  finance.yahoo.com
Is Amicus Therapeutics Headed for a Breakout?
November 3, 2021 |  stocknews.com
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:FOLD
CUSIP
03152W10
Employees
483
Year Founded
2002

Sales & Book Value

Annual Sales
$260.89 million
Book Value
$1.10 per share

Profitability

Net Income
$-276.85 million
Pretax Margin
-79.90%

Debt

Price-To-Earnings

Miscellaneous

Free Float
272,788,000
Market Cap
$2.91 billion
Optionable
Optionable

Company Calendar

Last Earnings
11/08/2021
Today
12/04/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
3/07/2022

Social Links


MarketRank

Overall MarketRank

2.10 out of 5 stars

Medical Sector

512th out of 1,390 stocks

Pharmaceutical Preparations Industry

237th out of 668 stocks

Analyst Opinion: 3.3Community Rank: 4.9Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -












Amicus Therapeutics (NASDAQ:FOLD) Frequently Asked Questions

Is Amicus Therapeutics a buy right now?

11 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Amicus Therapeutics in the last year. There are currently 5 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Amicus Therapeutics stock.
View analyst ratings for Amicus Therapeutics
or view top-rated stocks.

How has Amicus Therapeutics' stock been impacted by Coronavirus (COVID-19)?

Amicus Therapeutics' stock was trading at $8.05 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, FOLD shares have increased by 29.8% and is now trading at $10.45.
View which stocks have been most impacted by COVID-19
.

When is Amicus Therapeutics' next earnings date?

Amicus Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, March 7th 2022.
View our earnings forecast for Amicus Therapeutics
.

How were Amicus Therapeutics' earnings last quarter?

Amicus Therapeutics, Inc. (NASDAQ:FOLD) released its quarterly earnings data on Monday, November, 8th. The biopharmaceutical company reported ($0.19) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.18) by $0.01. Amicus Therapeutics had a negative net margin of 81.17% and a negative trailing twelve-month return on equity of 84.62%. During the same quarter in the prior year, the business posted ($0.22) earnings per share.
View Amicus Therapeutics' earnings history
.

What guidance has Amicus Therapeutics issued on next quarter's earnings?

Amicus Therapeutics issued an update on its FY 2021 earnings guidance on Tuesday, November, 30th. The company provided EPS guidance of for the period. The company issued revenue guidance of $300 million-$315 million, compared to the consensus revenue estimate of $310.30 million.

What price target have analysts set for FOLD?

11 analysts have issued twelve-month price targets for Amicus Therapeutics' stock. Their forecasts range from $12.00 to $27.00. On average, they expect Amicus Therapeutics' share price to reach $16.56 in the next year. This suggests a possible upside of 58.4% from the stock's current price.
View analysts' price targets for Amicus Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Amicus Therapeutics' key executives?

Amicus Therapeutics' management team includes the following people:
  • John Francis Crowley, Chairman & Chief Executive Officer
  • Bradley Lewis Campbell, President, Chief Operating Officer & Director (LinkedIn Profile)
  • Daphne E. Quimi, Chief Financial Officer
  • Jill Weimer, Chief Science Officer
  • Patrik S. Florencio, Senior VP, Global Chief Compliance & Risk Officer

What is John F. Crowley's approval rating as Amicus Therapeutics' CEO?

21 employees have rated Amicus Therapeutics CEO John F. Crowley on Glassdoor.com. John F. Crowley has an approval rating of 48% among Amicus Therapeutics' employees. This puts John F. Crowley in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Amicus Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amicus Therapeutics investors own include NVIDIA (NVDA), AcelRx Pharmaceuticals (ACRX), Gilead Sciences (GILD), Sangamo Therapeutics (SGMO), Sarepta Therapeutics (SRPT), AbbVie (ABBV), Exelixis (EXEL), Advanced Micro Devices (AMD), Inovio Pharmaceuticals (INO) and Novavax (NVAX).

What is Amicus Therapeutics' stock symbol?

Amicus Therapeutics trades on the NASDAQ under the ticker symbol "FOLD."

Who are Amicus Therapeutics' major shareholders?

Amicus Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Perceptive Advisors LLC (9.53%), Wellington Management Group LLP (8.72%), BlackRock Inc. (7.35%), Morgan Stanley (4.19%), Deutsche Bank AG (2.67%) and Janus Henderson Group PLC (2.53%). Company insiders that own Amicus Therapeutics stock include Bradley L Campbell, Bradley L Campbell, Burke W Whitman, Burke W Whitman, Daphne Quimi, Ellen Rosenberg, Hung Do, Jay Barth, John F Crowley, John F Crowley, Lynn Dorsey Bleil, Margaret G Mcglynn, Michael Raab and Samantha Prout.
View institutional ownership trends for Amicus Therapeutics
.

Which major investors are selling Amicus Therapeutics stock?

FOLD stock was sold by a variety of institutional investors in the last quarter, including Great Point Partners LLC, Deutsche Bank AG, BlackRock Inc., Two Sigma Advisers LP, Massachusetts Financial Services Co. MA, Voloridge Investment Management LLC, Longitude Cayman Ltd., and Primecap Management Co. CA. Company insiders that have sold Amicus Therapeutics company stock in the last year include Bradley L Campbell, Daphne Quimi, Hung Do, John F Crowley, Margaret G Mcglynn, and Samantha Prout.
View insider buying and selling activity for Amicus Therapeutics
or view top insider-selling stocks.

Which major investors are buying Amicus Therapeutics stock?

FOLD stock was bought by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Perceptive Advisors LLC, Artal Group S.A., Janus Henderson Group PLC, Nordea Investment Management AB, BioImpact Capital LLC, Sphera Funds Management LTD., and Two Sigma Investments LP. Company insiders that have bought Amicus Therapeutics stock in the last two years include Burke W Whitman, and Lynn Dorsey Bleil.
View insider buying and selling activity for Amicus Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Amicus Therapeutics?

Shares of FOLD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Amicus Therapeutics' stock price today?

One share of FOLD stock can currently be purchased for approximately $10.45.

How much money does Amicus Therapeutics make?

Amicus Therapeutics has a market capitalization of $2.91 billion and generates $260.89 million in revenue each year. The biopharmaceutical company earns $-276.85 million in net income (profit) each year or ($0.90) on an earnings per share basis.

How many employees does Amicus Therapeutics have?

Amicus Therapeutics employs 483 workers across the globe.

When was Amicus Therapeutics founded?

Amicus Therapeutics was founded in 2002.

What is Amicus Therapeutics' official website?

The official website for Amicus Therapeutics is www.amicusrx.com.

Where are Amicus Therapeutics' headquarters?

Amicus Therapeutics is headquartered at 1 Cedar Brook Drive, Cranbury NJ, 08512.

How can I contact Amicus Therapeutics?

Amicus Therapeutics' mailing address is 1 Cedar Brook Drive, Cranbury NJ, 08512. The biopharmaceutical company can be reached via phone at (215) 921-7600, via email at [email protected], or via fax at 609-662-2001.


This page was last updated on 12/4/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.